Policy

International Presenters Share Tips on Beefing Up Biosimilar Use

October 9th 2020

By Skylar Jeremias

As the United States continues to struggle to increase biosimilar uptake, presenters at the DIA 2020 Biosimilars Conference offered insight into what other countries have done to encourage biosimilar use.

Report: Biosimilar Savings Have Grown, but Uptake Barriers Remain

September 30th 2020

By Skylar Jeremias

Over the past decade, savings from biosimilars have grown; however, there remain barriers that prevent biosimilar savings from reaching their full potential, according to a report from the Association for Accessible Medicines.

Report: Germany Has Not Fully Realized Its Biosimilar Potential

September 29th 2020

By Deana Ferreri, PhD

Germany could eke out more gains from biosimilars on top of its already impressive savings, investigators write.

Stakeholders Joust Over Biosimilar Availability at PCOC20

September 25th 2020

By Tony Hagen

A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.

Patt: Payers Could Save More With Biosimilars

September 25th 2020

By Tony Hagen

Debra Patt, MD, PhD, MBA, discusses issues affecting biosimilar uptake at the Patient-Centered Oncology Care® 2020 virtual conference.

Report: Prescription Drug Costs Can Be Lowered Without Legislation

September 23rd 2020

By Skylar Jeremias

Much emphasis is placed on the value of congressional action to reduce prescription costs, but the Center for American Progress suggests there is an existing toolkit to accomplish this objective.

Report: Lack of Biosimilar Competition Contributed to Billions in Lost Savings

September 21st 2020

By Skylar Jeremias

The United States has missed out on almost $20 billion in savings as a result of not having a competitive biosimilar market, according to findings from the Pacific Research Institute.

ACR Survey Reveals Patient Knowledge Gaps on Biosimilars

September 16th 2020

By Skylar Jeremias

Many patients with rheumatic diseases are unsure whether their prescriptions are biosimilars, suggesting more efforts in patient education are needed.

Expert Opinion Roundup: Overcoming Barriers to Biosimilar Uptake

September 7th 2020

By Skylar Jeremias

This summer, The Center for Biosimilars® interviewed several experts for their opinions on the current need for biosimilars and how companies are working to overcome barriers to uptake. Here are some highlights.

Part 2: Surya Singh, MD, on Whether Biosimilars Will Lower Drug Costs

September 3rd 2020

Surya Singh, MD, president and owner of Singh Healthcare Advisors LLC in Lexington, Massachusetts, discussed the future for the US adalimumab market and whether biosimilars can deliver on the promise of lower cost health care.